Clik here to view.
What Can Washington Do to Revitalize Biotech? Q&A With Gov. Inslee
Luke Timmerman Seattle biotech isn’t what it used to be. A decade ago, Seattle was basking in the glory of one of the biggest pharmaceutical success stories ever—etanercept (Enbrel). The …
View ArticleClik here to view.
Report: Dendreon Looking to Get Acquired
Luke Timmerman Dendreon is apparently crying uncle, and seeking some other company to take it over. The Seattle-based pioneer of cancer immunotherapy (NASDAQ: DNDN) is working with JP Morgan …
View ArticleClik here to view.
Immune Design Grabs $32.5M, Cashing in on Cancer Immunotherapy Rush
Luke Timmerman Seattle-based Immune Design imagines growing into one of the next big players in immunotherapy for cancer, and today it’s secured some big venture bucks to see if it …
View ArticleClik here to view.
Dendreon Cuts 150 Jobs, As Prostate Cancer Drug Sales Decline
Luke Timmerman Dendreon once had 2,000 employees at its peak, less than three years ago. Its stock was once over $40 a share. Analysts once predicted its prostate cancer drug …
View ArticleClik here to view.
Juno Therapeutics Grabs $120M to Coax Immune System to Fight Cancer
Luke Timmerman Scientists have tried for decades to coax the body’s immune system to hunt down and kill cancer cells, much in the same way it fights viruses and bacteria. …
View ArticleClik here to view.
Join Xconomy for ‘What’s Hot in Cancer Immunotherapy’ on April 22
Luke Timmerman Two or three years ago, most biotech pros would have scoffed if you had predicted a revival of cancer immunotherapy. Dendreon flopped, right? Oh, how quickly things change. …
View ArticleClik here to view.
Hiring in Biotech is Tricky. But Algorithms Won’t Save the Day
Luke Timmerman People who appreciate baseball stats agree: Jonny Gomes of the Boston Red Sox is a below-average player. Yet, if you pay attention to his intangibles, he looks …
View ArticleOncoGenex Retrenches, and Searches for Answers, After Failed Trial
Ben Fidler There are several harsh lessons to be learned in drug development, and OncoGenex learned perhaps the most brutal one of all: a knockout Phase 2 trial doesn’t guarantee …
View ArticleWhat Seattle Needs (Part 1): “Semi-Successful” Biotech Companies
Stewart Lyman I know what you’re thinking: that’s a pretty strange headline. Why would a city want to attract or build companies that are only “semi-successful?” Wouldn’t it want …
View ArticleWhat Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure
Stewart Lyman Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people …
View ArticleClik here to view.
MassChallenge Winner From MIT Aims to Kill Cancer With a “Squeeze”
Ben Fidler Among the slew of challenges in drug development, there’s this: how can you efficiently get a big molecule, like a protein or nucleic acid, into a cell? That (Read more...)
View ArticleClik here to view.
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind”
Alex Lash Biotech companies rarely go bankrupt. Sitting where I sit, that bit of conventional wisdom comes around every so often, although it doesn’t generate quite the same buzz as (Read more...)
View ArticleClik here to view.
Larry Corey, Cofounder of 2014 Top Biotech Juno: “It’s No Outlier”
Alex Lash Xconomy doesn’t have annual awards (the X-ies, anyone?), but I don’t have any hesitation naming Juno Therapeutics (NASDAQ: JUNO) the biotech company of the year for (Read more...)
View ArticleClik here to view.
Dendreon Gets $296M Bid From Valeant as Bankruptcy Auction Looms
Ben Fidler It looks like someone is interested in salvaging Provenge after all. The ever-acquisitive Valeant Pharmaceuticals (NYSE: VRX) made a surprising $296 million all-cash offer late Thursday to...
View ArticleClik here to view.
End of Dendreon: Valeant’s $400M is Sole Offer, Purchase is Next
Alex Lash There will be no auction for bankrupt biotech Dendreon (NASDAQ: DNDNQ). Valeant Pharmaceuticals (NYSE: VRX) has made the only bid for the Seattle company, and with (Read more...)
View Article
